1615697-41-0

Basic information

• Product Name: N-(4-FLUOROPHENYL)-3-(3-NITROPHENYL)ACRYLAMIDE
• Synonyms: N-(4-FLUOROPHENYL)-3-(3-NITROPHENYL)ACRYLAMIDE;(2E)-N-(4-fluorophenyl)-3-(3-nitrophenyl)prop-2-enamide
• CAS NO: 1615697-41-0
• Molecular Formula: C₁₅H₁₁FN₂O₃
• Molecular Weight: 286.26
• Mol File: 1615697-41-0.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-(4-FLUOROPHENYL)-3-(3-NITROPHENYL)ACRYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-FLUOROPHENYL)-3-(3-NITROPHENYL)ACRYLAMIDE(1615697-41-0)
• EPA Substance Registry System: N-(4-FLUOROPHENYL)-3-(3-NITROPHENYL)ACRYLAMIDE(1615697-41-0)

Safety Data

• Hazardous Substances Data: 1615697-41-0(Hazardous Substances Data)

Usage

General Description

(E)-N-(4-fluorophenyl)-3-(3-nitrophenyl)acrylamide is an organic compound with the chemical formula C16H11FN2O3. It is a yellow solid that is commonly used in organic synthesis and medicinal chemistry. (E)-N-(4-fluorophenyl)-3-(3-nitrophenyl)acrylamide has potential applications in pharmaceutical research, as it possesses both a fluorophenyl group and a nitrophenyl group, which are known to have biological activity. The (E)-N-(4-fluorophenyl)-3-(3-nitrophenyl)acrylamide may serve as a building block for the synthesis of various biologically active molecules and pharmaceutical drugs. Its specific properties and applications make it a valuable and versatile chemical in the field of medicinal chemistry and drug discovery.

Upstream product

• 555-68-0 (E)-3-Nitrocinnamic acid 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 1615697-23-8 2-bromo-N-(3-{(1E)-3-oxo-3-[(4-fluorophenyl)amino]prop-1-en-1-yl}phenyl)-acrylamide 
• 1175900-96-5 (E)-3-(3-aminophenyl)-N-(4-fluorophenyl)acrylamide 

Relevant articles and documents

Design, synthesis and biological evaluation of arylcinnamide hybrid derivatives as novel anticancer agents

The combination of two pharmacophores into a single molecule represents one of the methods that can be adopted for the synthesis of new anticancer molecules. A series of novel antiproliferative agents designed by a pharmacophore hybridization approach, combining the arylcinnamide skeleton and an α-bromoacryloyl moiety, was synthesized and evaluated for its antiproliferative activity against a panel of seven human cancer cell lines. In addition, the new derivatives were also active on multidrug-resistant cell lines over-expressing P-glycoprotein. The biological effects of various substituents on the N-phenyl ring of the benzamide portion were also described. In order to study the possible mechanism of action, we observed that 4p slightly increased the Reactive Oxygen Species (ROS) production in HeLa cells, but, more importantly, a remarkable decrease of intracellular reduced glutathione content was detected in treated cells compared with controls. These results were confirmed by the observation that only thiol-containing antioxidants were able to significantly protect the cells from induced cell death. Altogether our results indicate that the new derivatives are endowed with good anticancer activity in vitro, and their properties may result in the development of new cancer therapeutic strategies.